STOCK TITAN

Corcept Therapeutics Inc - CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.

Corcept Therapeutics Inc. (NASDAQ: CORT) is a commercial-stage pharmaceutical company dedicated to the discovery and development of innovative medications that target the underlying effects of abnormal cortisol levels. Cortisol, a hormone essential for various bodily functions, can become dysregulated and contribute to a range of serious health conditions, including metabolic disorders, oncologic diseases, and neuropsychiatric illnesses. Corcept leverages its deep scientific expertise to address these challenges by developing drugs that modulate the glucocorticoid receptor (GR), a key mediator of cortisol's effects.

Core Business Areas

Corcept's business model is centered on the research, development, and commercialization of GR antagonists. The company’s flagship product, mifepristone, is approved for the treatment of hypercortisolism in certain conditions. Beyond this, Corcept has built an extensive pipeline of over 300 proprietary molecules, each designed to selectively block the GR without affecting the progesterone receptor. This specificity minimizes side effects and enhances therapeutic potential.

Addressing Unmet Medical Needs

Corcept’s innovative compounds are being evaluated in clinical trials for their ability to treat a variety of severe and life-threatening conditions. These include:

  • Hypercortisolism: A disorder characterized by excessive cortisol levels, often linked to Cushing's syndrome.
  • Oncologic Applications: Advanced ovarian cancer, prostate cancer, and other malignancies where cortisol plays a role in disease progression.
  • Neuropsychiatric Disorders: Conditions such as post-traumatic stress disorder (PTSD), mild cognitive impairment, and Alzheimer’s disease.
  • Metabolic Diseases: Non-alcoholic steatohepatitis (NASH) and other metabolic syndromes influenced by cortisol dysregulation.

Scientific Approach and Differentiation

What sets Corcept apart in the competitive pharmaceutical landscape is its singular focus on GR antagonism. Unlike traditional therapies that may broadly target hormonal pathways, Corcept’s compounds are designed to selectively block the GR, thereby mitigating the adverse effects of excess cortisol while preserving other hormonal functions. This approach is supported by extensive scientific literature and represents a promising avenue for treating diseases with high unmet medical needs.

Market Position and Growth Potential

Operating in the dynamic pharmaceutical industry, Corcept occupies a niche position as a pioneer in cortisol modulation therapies. Its focus on conditions with limited treatment options provides a strategic advantage, as does its robust pipeline of proprietary molecules. However, the company faces challenges typical of the sector, including regulatory approvals, competition from larger pharmaceutical firms, and the inherent risks of clinical trial outcomes. Despite these hurdles, Corcept’s unique scientific approach and targeted focus position it as a significant player in its field.

Commitment to Innovation

Corcept’s commitment to advancing medical science is evident in its investment in research and development. By exploring the role of cortisol in various diseases and developing compounds that address these mechanisms, the company aims to deliver transformative therapies that improve patient outcomes. Its strategic focus on unmet medical needs underscores its potential to make a lasting impact on the healthcare landscape.

Conclusion

Corcept Therapeutics Inc. exemplifies the intersection of scientific innovation and patient-focused care. Through its pioneering work in cortisol modulation, the company addresses some of the most pressing challenges in modern medicine. With a strong foundation in research, a growing pipeline of proprietary compounds, and a commitment to addressing unmet medical needs, Corcept is well-positioned to contribute significantly to the pharmaceutical industry.

Rhea-AI Summary
Corcept Therapeutics Incorporated has appointed Monica Tellado as President, Emerging Markets. She will be responsible for global commercial lead in therapeutics in metabolism and neurology. Corcept also announced the initiation of a Phase 2b trial of its selective cortisol modulator miricorilant and expects results from its Phase 2 DAZALS study next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
management acquisition
-
Rhea-AI Summary
Corcept Therapeutics has announced the initiation of MONARCH, a Phase 2b trial of miricorilant in patients with non-alcoholic steatohepatitis (NASH). The trial will evaluate the efficacy and safety of miricorilant in adult patients with biopsy-confirmed NASH, with the primary endpoint being reduction in liver fat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
-
Rhea-AI Summary
Corcept Therapeutics to report Q3 financial results and provide corporate update on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
Rhea-AI Summary
Corcept Therapeutics reports Q2 2023 revenue of $117.7 million, a 14% increase from Q2 2022. Raises 2023 revenue guidance to $455-$470 million. Net income per share of $0.25 (diluted). Cash and investments of $363.3 million as of June 30, 2023. Purchase of 6.6 million shares of Corcept common stock for $145.4 million. Enrollment completed in Phase 3 GRACE trial of relacorilant for Cushing's syndrome. Positive feedback on CATALYST trial. Enrollment continues in ROSELLA trial for ovarian cancer. Enrollment continues in DAZALS trial for ALS. Enrollment continues in Phase 1b trial of miricorilant for NASH. Conference call on August 2, 2023, at 5:00 p.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.91%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Summary
Corcept Therapeutics announces positive results from Phase 1b study of miricorilant in NASH patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) reported its Q1 2023 results, with revenue of $105.7 million, a raised 2023 revenue guidance of $435 - $455 million, and net income per common share of $0.14. The company also purchased 6.6 million shares of its common stock for $145.4 million in April 2023. Clinical development updates include upcoming data releases and enrollment progress in various trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) announced it will report its first quarter financial results and corporate update on May 3, 2023, at 5:00 p.m. Eastern Time. A conference call will provide insights into the company's current financial standing and future plans. Participants must register in advance for the call to receive a unique access PIN. Additionally, a listen-only webcast will be available for those unable to attend the call. Corcept is known for its proprietary cortisol modulators aimed at treating serious health disorders like Cushing's syndrome, cancer, and PTSD. Its drug Korlym® was the first approved treatment for Cushing’s syndrome in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
Rhea-AI Summary

Corcept Therapeutics, based in Menlo Park, California, announced the completion of its tender offer to purchase up to 7,500,000 shares of its common stock. The offer concluded on March 31, 2023, with a final count revealing that 6,610,369 shares were validly tendered. Corcept has accepted all those shares at a price of $22.00 each, resulting in an aggregate cost of approximately $145.4 million. This buyback accounts for about 6% of the company's total shares outstanding, which were 101,545,296 after the transaction. The tender offer involved Piper Sandler & Co. as the dealer manager and D.F. King & Co., Inc. as the information agent.

Corcept is known for developing medications that modulate cortisol effects, addressing serious conditions like Cushing’s syndrome and various cancers. The company continues to advance its clinical trials for additional treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
none

FAQ

What is the current stock price of Corcept Therapeutics (CORT)?

The current stock price of Corcept Therapeutics (CORT) is $74.45 as of April 4, 2025.

What is the market cap of Corcept Therapeutics (CORT)?

The market cap of Corcept Therapeutics (CORT) is approximately 7.9B.

What does Corcept Therapeutics specialize in?

Corcept Therapeutics specializes in developing drugs that modulate the effects of cortisol to treat metabolic, oncologic, and neuropsychiatric disorders.

What is Corcept’s flagship product?

Corcept’s flagship product is mifepristone, approved for treating hypercortisolism in specific conditions.

What makes Corcept’s approach unique?

Corcept focuses on selective glucocorticoid receptor (GR) antagonism, which targets cortisol's effects without affecting other hormonal pathways.

What diseases are Corcept’s compounds being developed to treat?

Corcept’s compounds are being developed to treat hypercortisolism, advanced cancers, PTSD, Alzheimer’s disease, and metabolic disorders like NASH.

How does Corcept generate revenue?

Corcept generates revenue through the commercialization of its approved drugs and ongoing development of its proprietary pipeline.

What challenges does Corcept face in its industry?

Corcept faces challenges such as regulatory approvals, competition from larger pharmaceutical companies, and the risks inherent in clinical trials.

What is the significance of glucocorticoid receptor antagonism?

Glucocorticoid receptor antagonism helps mitigate the adverse effects of excess cortisol, offering potential treatments for various serious conditions.

What is Corcept’s competitive advantage?

Corcept’s competitive advantage lies in its focus on cortisol modulation and its extensive pipeline of proprietary GR antagonists.

What industries does Corcept Therapeutics operate in?

Corcept operates in the pharmaceutical and biotechnology industries, focusing on drug development for unmet medical needs.

How does Corcept contribute to addressing unmet medical needs?

Corcept develops innovative therapies targeting diseases with limited treatment options, such as hypercortisolism and advanced cancers.
Corcept Therapeutics Inc

Nasdaq:CORT

CORT Rankings

CORT Stock Data

7.87B
93.36M
11.44%
81.8%
15.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY